A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA